Beyond The Numbers: 4 Analysts Discuss Privia Health Gr Stock
Analyst Ratings Overview: Recent evaluations of Privia Health Group by four analysts show a mix of bullish and bearish sentiments, with the average 12-month price target rising slightly to $29.75, indicating varied expectations for the company's stock performance.
Financial Performance Indicators: Privia Health Group demonstrates strong revenue growth of 23.4% over three months, but faces challenges with low return on equity (0.4%) and return on assets (0.22%), despite maintaining a favorable debt-to-equity ratio of 0.01.
Trade with 70% Backtested Accuracy
Analyst Views on PRVA
About PRVA
About the author
BMO Capital Begins Coverage of Privia Health Group with Outperform Rating and Sets Price Target at $30
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Evercore ISI Group Reaffirms Outperform Rating for Privia Health Group, Increases Price Target to $30
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them succeed.
Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies for better trading outcomes.
Market Winning Tools: The platform is designed to equip traders with the tools and information necessary to make informed decisions in the stock market.
Privia Health: Overview of Q3 Earnings
Quarterly Profit Report: Privia Health Group Inc. reported a third-quarter profit of $6.9 million, equating to 5 cents per share.
Earnings vs. Expectations: The earnings fell short of Wall Street expectations, which anticipated earnings of 6 cents per share.
Revenue Performance: The company posted revenue of $580.4 million, exceeding analyst forecasts of $497.6 million.
Full-Year Revenue Outlook: Privia Health expects its full-year revenue to be between $2.05 billion and $2.1 billion.
Barclays Keeps Equal-Weight Rating on Privia Health Group (PRVA)
Barclays Coverage: Barclays has maintained an Equal-Weight recommendation for Privia Health Group (NasdaqGS:PRVA) as of October 9, 2025, with an average one-year price target of $31.19/share, indicating a potential upside of 28.89% from its current price of $24.20/share.
Fund Sentiment and Ownership: There are 570 funds reporting positions in Privia Health Group, with a 7.55% increase in ownership over the last quarter. Notable shareholders include Durable Capital Partners and IJR - iShares Core S&P Small-Cap ETF, with varying changes in their portfolio allocations.
Privia Health Scheduled to Announce Q3 2025 Results on Thursday, November 6
Financial Results Announcement: Privia Health Group, Inc. will release its financial results for the third quarter and nine-month period on November 6, 2025, before market opening, with a press release at 7:00 am ET.
Conference Call Details: A conference call to discuss the results and future outlook will take place at 8:00 am ET on the same day, with options for live participation and on-demand listening available afterward.
Projected Target Price for FYC Analyst: $104
ETF Target Price Analysis: The First Trust Small Cap Growth AlphaDEX Fund ETF (FYC) has an implied analyst target price of $104.03 per unit, indicating a potential upside of 14.43% from its current trading price of $90.91.
Notable Holdings with Upside: Key underlying holdings such as Privia Health Group Inc (PRVA), Huron Consulting Group Inc (HURN), and Arcutis Biotherapeutics Inc (ARQT) show significant upside potential based on analyst target prices, with expected increases of 20.70%, 16.18%, and 15.13% respectively.
BMO Capital Begins Coverage of Privia Health Group with Outperform Rating and Sets Price Target at $30
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Evercore ISI Group Reaffirms Outperform Rating for Privia Health Group, Increases Price Target to $30
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them succeed.
Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies for better trading outcomes.
Market Winning Tools: The platform is designed to equip traders with the tools and information necessary to make informed decisions in the stock market.
Privia Health: Overview of Q3 Earnings
Quarterly Profit Report: Privia Health Group Inc. reported a third-quarter profit of $6.9 million, equating to 5 cents per share.
Earnings vs. Expectations: The earnings fell short of Wall Street expectations, which anticipated earnings of 6 cents per share.
Revenue Performance: The company posted revenue of $580.4 million, exceeding analyst forecasts of $497.6 million.
Full-Year Revenue Outlook: Privia Health expects its full-year revenue to be between $2.05 billion and $2.1 billion.
Barclays Keeps Equal-Weight Rating on Privia Health Group (PRVA)
Barclays Coverage: Barclays has maintained an Equal-Weight recommendation for Privia Health Group (NasdaqGS:PRVA) as of October 9, 2025, with an average one-year price target of $31.19/share, indicating a potential upside of 28.89% from its current price of $24.20/share.
Fund Sentiment and Ownership: There are 570 funds reporting positions in Privia Health Group, with a 7.55% increase in ownership over the last quarter. Notable shareholders include Durable Capital Partners and IJR - iShares Core S&P Small-Cap ETF, with varying changes in their portfolio allocations.
Privia Health Scheduled to Announce Q3 2025 Results on Thursday, November 6
Financial Results Announcement: Privia Health Group, Inc. will release its financial results for the third quarter and nine-month period on November 6, 2025, before market opening, with a press release at 7:00 am ET.
Conference Call Details: A conference call to discuss the results and future outlook will take place at 8:00 am ET on the same day, with options for live participation and on-demand listening available afterward.
Projected Target Price for FYC Analyst: $104
ETF Target Price Analysis: The First Trust Small Cap Growth AlphaDEX Fund ETF (FYC) has an implied analyst target price of $104.03 per unit, indicating a potential upside of 14.43% from its current trading price of $90.91.
Notable Holdings with Upside: Key underlying holdings such as Privia Health Group Inc (PRVA), Huron Consulting Group Inc (HURN), and Arcutis Biotherapeutics Inc (ARQT) show significant upside potential based on analyst target prices, with expected increases of 20.70%, 16.18%, and 15.13% respectively.
